Table 2 Correlation between immune related proteins and objective response rate (ORR) in 30 advanced HER2-positive breast cancer
Parameters | Responders (n = 25) | Non-responders (n = 5) | p value |
|---|---|---|---|
Age at treatment | |||
 ≤ 62 vs > 62 | 12 (48.0%) vs 13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
Degree of progress | |||
 Locally advanced vs visceral metastases | 9 (36.0%)/16 (64.0%) | 1 (20.0%)/4 (80.0%) | 0.505 |
Stage | |||
 IIIC or IV vs recurrence | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
ER | |||
 Negative vs positive | 16 (64.0%)/9 (36.0%) | 2 (40.0%)/3 (60.0%) | 0.334 |
PgR | |||
 Negative vs positive | 17 (68.0%)/8 (32.0%) | 3 (60.0%)/2 (40.0%) | 0.740 |
Ki67 | |||
 Negative vs positive | 14 (56.0%)/11 (44.4%) | 2 (40.0%)/3 (60.0%) | 0.529 |
Treatment line | |||
 First vs other | 16 (64.0%)/9 (36.0%) | 1 (20.0%)/4 (80.0%) | 0.074 |
CD8 | |||
 Negative vs positive | 16 (64.0%)/9 (36.0%) | 5 (100.0%)/0 (0.0%) | 0.116 |
FOXP3 | |||
 Negative vs positive | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
CFR | |||
 Low/high | 10 (40.0%)/15 (60.0%) | 5 (100.0%)/0 (0.0%) | 0.013 |
PD1 | |||
 Negative vs positive | 11 (44.0%)/14 (56.0%) | 3 (60.0%)/2 (40.0%) | 0.529 |
PD-L1 | |||
 Negative vs positive | 17 (68.0%)/8 (32.0%) | 2 (40.0%)/3 (60.0%) | 0.250 |
CD163 | |||
 Negative vs positive | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
PTEN | |||
 Negative vs positive | 13 (52.0%)/12 (48.8%) | 4 (80.0%)/1 (20.0%) | 0.264 |
LAG3 | |||
 Negative vs positive | 16 (64.0%)/9 (36.0%) | 4 (80.0%)/1 (20.0%) | 0.505 |